VX-702: Selective p38α MAPK Inhibitor for Inflammation Research

Executive Summary: VX-702 (A8687) is a potent and highly selective p38α MAPK inhibitor with an IC50 of 4–20 nM, designed for precision modulation of inflammatory signaling (product_spec). It acts via ATP-competitive binding, conferring superior specificity over previous inhibitors (paper). VX-702 suppresses IL-6, IL-1β, and TNFα production in ex vivo human assays and preserves platelet mitochondria during storage (product_spec). In vivo, it reduces joint erosion and inflammation in mouse arthritis models, with oral dosing efficacy comparable to methotrexate. Its dual-action mechanism also enhances dephosphorylation of p38α, offering both direct kinase inhibition and increased phosphatase activity (paper).

Biological Rationale

p38α MAP kinase (MAPK14) is a central component in cellular stress and inflammatory signaling. Activation of p38α MAPK leads to phosphorylation events that drive production of pro-inflammatory cytokines such as IL-6, IL-1β, and TNFα (paper). Dysregulated p38 signaling is implicated in autoimmune diseases, including rheumatoid arthritis, and in tissue injury contexts like myocardial ischemia-reperfusion. Selectively inhibiting p38α MAPK is a validated strategy for dissecting inflammation mechanisms and for preclinical therapeutic evaluation (internal_article).

Mechanism of Action of VX-702

VX-702 is an ATP-competitive inhibitor, binding the active site of p38α MAPK with enhanced affinity due to its difluorophenyl and pyridine-3-carboxamide moieties (product_spec). This binding stabilizes an inactive conformation of the kinase’s activation loop, which not only blocks catalytic activity but also renders the phospho-threonine residue accessible to the PPM-type phosphatase WIP1. This dual-action effect leads to both suppression of kinase activity and an increased rate of dephosphorylation, distinguishing VX-702 from traditional inhibitors that only block the active site (paper).

Evidence & Benchmarks

• VX-702 inhibits p38α MAPK with an IC50 of 4–20 nM in biochemical assays (source: product_spec).
• Demonstrates ATP-competitive inhibition and stabilizes the inactive conformation of the p38α activation loop (source: paper).
• Reduces IL-6, IL-1β, and TNFα release in LPS-primed human blood assays in a dose-dependent manner (source: product_spec).
• In murine collagen-induced arthritis models, oral VX-702 matches the efficacy of methotrexate and prednisolone in reducing joint erosion and inflammation (source: product_spec).
• Minimizes myocardial damage after ischemia-reperfusion injury by selective p38α MAPK inhibition, without affecting ERK or JNK pathways (source: product_spec).
• Preserves mitochondrial and functional parameters in stored platelets, restoring properties after agitation interruption without inducing aggregation or calcium mobilization (source: product_spec).
• Pharmacokinetic studies in isolated perfused rat kidneys show linear excretion and reabsorption, independent of organic anion or cation transporters (source: product_spec).
• Crystallography reveals that VX-702-bound p38α exposes the phospho-threonine for rapid dephosphorylation by WIP1, confirming the dual-action mechanism (source: paper).

For a mechanistic deep dive and model-specific data, see the internal article VX-702: Advancing p38α MAPK Inhibition for Precision Inflammation Research, which this piece updates by providing the latest structural and dual-action mechanistic evidence.

For protocols on practical cell-based assays, Optimizing Cell Assays with VX-702, P38α MAPK Inhibitor offers workflow-specific recommendations, whereas this dossier focuses on molecular and cross-system benchmarks.

For comparative ATP-competitive inhibitor data, see VX-702: Selective, ATP-Competitive p38α MAPK Inhibitor, which is extended here by detailing the phosphatase interaction mechanism.

Applications, Limits & Misconceptions

VX-702 enables precise dissection of inflammatory signaling in cell and animal models. It is suitable for: (1) inhibition of pro-inflammatory cytokine production (e.g., IL-6, IL-1β, TNFα); (2) preclinical studies in rheumatoid arthritis and myocardial ischemia-reperfusion injury; and (3) platelet storage and function assays (product_spec).

Common Pitfalls or Misconceptions

• VX-702 does not inhibit ERK or JNK pathways at effective concentrations—selectivity is for p38α only (source: product_spec).
• It is not suitable for direct diagnostic or clinical use; intended strictly for research applications (source: product_spec).
• Long-term storage in solution is not recommended; compound stability is optimal as solid at -20°C (source: product_spec).
• VX-702 does not directly induce platelet aggregation or calcium mobilization (source: product_spec).
• Its pharmacokinetics in rat kidney studies may not fully predict behavior in other organs or species (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• assay: Biochemical p38α MAPK inhibition | value_with_unit: IC50 = 4–20 nM | applicability: enzymatic activity assays | rationale: Defines potency for target engagement | source_type: product_spec
• assay: Cytokine suppression (IL-6, IL-1β, TNFα) | value_with_unit: Dose-dependent, typically 10–100 nM | applicability: ex vivo LPS-primed human blood | rationale: Benchmark for cellular pathway inhibition | source_type: product_spec
• assay: Platelet mitochondrial preservation | value_with_unit: ≥10 nM | applicability: platelet storage models | rationale: Prevents loss of metabolic and functional parameters | source_type: product_spec
• assay: In vivo arthritis model | value_with_unit: Oral, 10–30 mg/kg daily | applicability: mouse collagen-induced arthritis | rationale: Matches efficacy of methotrexate/prednisolone | source_type: product_spec
• assay: Myocardial ischemia-reperfusion injury | value_with_unit: 1–10 mg/kg (oral or IV) | applicability: mouse/rat cardiac models | rationale: Reduces infarct size via selective p38 inhibition | source_type: product_spec
• assay: Stock solution solubility | value_with_unit: >20.2 mg/mL in DMSO | applicability: compound preparation | rationale: Ensures adequate working concentration | source_type: product_spec
• assay: Storage recommendation | value_with_unit: -20°C (solid form) | applicability: all uses | rationale: Maintains compound integrity | source_type: product_spec

Conclusion & Outlook

VX-702 exemplifies a new generation of p38α MAPK inhibitors that combine high target selectivity, potent cytokine suppression, and a dual-action mechanism facilitating both kinase inhibition and enhanced dephosphorylation. This supports its ongoing adoption in inflammation and cardiovascular research, as well as in advanced cell and animal models. The dual-action effect, recently elucidated via structural studies, may inform future inhibitor design for increased specificity in kinase-targeted therapies (paper). For full product details and ordering, consult APExBIO's VX-702 product page. All evidence presented is intended for research use and not for diagnostic or clinical application.